RxSight, Inc. Common Stock (RXST)
RxSight, Inc. is a medical device company specializing in the development and commercialization of innovative ophthalmic products. Its primary focus is on improving outcomes for patients undergoing cataract surgery through its flagship product, the Light Adjustable Lens (LAL), which allows customization and post-operative adjustments to optimize visual results. The company’s technology aims to enhance the precision and flexibility of cataract treatment.
Company News
DJS Law Group is investigating RxSight, Inc. for potential securities law violations after the company reported significant financial declines, including reduced sales of Light Delivery Devices and lowered annual financial guidance.
Faruqi & Faruqi is investigating potential securities law violations by RxSight after the company reported significant sales declines and lowered financial guidance, causing its stock price to drop 37.8%.
RxSight reported Q2 2025 financial results with mixed performance, experiencing a 4% revenue decline but improving gross margins and growing Light Adjustable Lens procedure volume by 13%.
Does RxSight, Inc. (RXST) have what it takes to be a top stock pick for momentum investors? Let's find out.
RxSight, Inc. (NASDAQ:NASDAQ:RXST) Q1 2022 Earnings Conference Call May 5, 2022 16:30 ET Company Participants Philip Taylor - Investor Relations Ron Kurtz - President and Chief Executive...